Articles On Acrux (ASX:ACR)

Momentum investing involves taking advantage of, and making profits from, upward trends in a stock. The strategy takes the position that the stock market’s recent winners will remain winners. Note that there is a big difference between mome...

This week’s Bulls N’ Bears ASX Runner of the Week is… Regeneus Ltd. Its share price surged 220 per cent to join fellow movers and shakers Acrux Ltd and Perpetual Resources.

Specialty pharmaceutical company Acrux (ASX: ACR) and its partner TruPharma have launched a generic version of Aczone 5% Gel on the US market to treat acne vulgaris. Known as Dapsone 5% Gel, the prescription topical medicine was created to...

Acrux Ltd (ASX: ACR) shares are avoiding the market weakness and rocketing higher on Wednesday. In morning trade, the ASX healthcare stock was up as much as 110% to 9.9 cents. To put that into context, a $10,000 investment yesterday aftern...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Momentum trading involves taking advantage of, and making profits from, upward trends in a stock. It involves betting that the stock market’s recent winners will remain winners. One of the best known momentum traders in the world is hedge f...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today.   ICYMI Leade...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Ask any chief of a development-stage biotech about the prospect of a partnering or licencing deal and they will refer to a multitude of discussion with big pharma – all couched in suitably vague terms. But when Dimerix (ASX:DXB) chief Dr Ni...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Tim Boreham outlines the rise and fall of IDT Australia, and its potential revival in the cannabis and psychedelic drug market. by Tim Boreham ASX Code: ((IDT)) Share price: 6.7 cents Shares on issue: 351,337,149 Market cap: $23.5m Chief ex...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

The ASX was higher by around 2.5% in July The best sectors were Tech and Energy We look at the best and worst performing ASX stocks for the month For the month of July, most major indexes on the ASX rose by around 2.5%. Name % Change...

S&P/ASX 200 closes in the red today: -0.35%, as US stock markets enjoy a July 4 chilli dog, or something Sectors-wise, Telcos are ringing in the gainz… annnd that’s about it. Okay, Utilities are going alright  Standout stocks: Krakatoa...

Acrux (ACR) receives approval from the US FDA to review a generic version of its nitroglycerin ointment at 0.4 per cent concentration The company applied for an abbreviated new drug application for the generic version, if approved by the...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

By Tim Boreham ASX code: ((DXB)) Share price: 7.0c Shares on issue: 320,748,666* Market cap: $22.5m Chief executive officer: Dr Nina Webster Board: Hugh Alsop (chair), Dr Webster, Dr Sonia Poli, Clinton Snow Financials (March quarter 2023):...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week   Earlier this week, Pfizer surprised the market by say...

The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit   Medicare, telehealth and mental...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Acrux (ACR) reaches agreement for EUR 4.10 million (A$6.41 million) buyout of future Lenzetto royalties Lenzetto is used to treat oestrogen deficiency symptoms in postmenopausal women Acrux CEO and MD Michael Kotsanis said the deal im...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Acrux (ACR) and its partner, Padagis, launch a prilocaine and lidocaine cream product in the United StatesThe cream is used as a topical anaesthetic on the skin for numbing or as a pre-treatment for infiltration anaesthesiaThe company says...

Highlights The ASX 200 benchmark index closed in the green today (21 December), gaining 90.80 points or 1.29% to end at 7,115.10 points. Over the last five days, the index has lost 1.88% and 3.26% over the last 52 weeks. Utilities was...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

ASX 200 bounces back to grind out a 0.47% win for the day HitIQ’s new deals look set to cement its place in professional sports Star gets some heartburn-inducing mail from regulators in Queensland If you’re like me and can’t read the word...

Benchmark finishes up after fierce struggle for buoyancy Absolutely no one shocked to learn Star’s worn out its welcome in QLD A solid arvo by little league miners was a well-timed boost It’s been a somewhat indecisive day for Aussie mark...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Queen Elizabeth II soared off into the heavens Classic Minerals pulls off an amazing impersonation of Her Maj MinRes does absolutely nothing, but banks $1.5bn in value anyway   What a cracker of a day. This morning was an absolute rager,...

Acrux and Lumos are waiting for FDA’s approvals Paradigm will present Phase 2 results Neuren commences Phase 2 trials Acrux (ASX:ACR) says the FDA has accepted its application for a generic version of coldsore treatment, ‘Acyclovir Cream,...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Pharmaceutical company Acrux (ACR) enters an exclusive commercial agreement with US-based Padagis for one of its products Under the agreement, Padagis will commercialise Acrux’s product and will be responsible for sales, distribution and c...

Antisense announces positive study of ATL1102 Acrux to launch a new product in the US MedAdvisor gets new CEO  Antisense Therapeutics (ASX:ANP) announced a successful study into a new muscle disease indication for its lead drug, ATL1102....

Highlights Firebrick secures patent in Malaysia for Nasodine® Nasal Spray as a treatment and preventative for common cold Nasodine is now protected in 26 countries, with China, Singapore, Japan, and Canada on the pending list Nasodine...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

When it comes to analysing company results, interpretations can differ as widely as Russian news agent Pravda’s reporting of the Ukraine conflict relative to the Kyiv Independent’s. Take the reformed generic drug house Mayne Pharma (ASX:MYX...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...